

## BIOGRAPHICAL SKETCH

<b>NAME</b> Johann S. de Bono MBChB, F.R.C.P., M.Sc., Ph.D. FMedSci.	<b>POSITION TITLE</b> Professor in Experimental Cancer Medicine and Honorary Consultant Medical Oncologist, Royal Marsden Hospital and Institute of Cancer Research, Sycamore House, Downs Road, Sutton, Surrey, SM2 5PT, UK		
<b>EDUCATION/TRAINING</b>			
<b>INSTITUTION AND LOCATION</b>	<b>DEGREE</b>	<b>YEAR(s)</b>	<b>FIELD OF STUDY</b>
Glasgow University Medical School, Scotland, UK.	MB ChB	1984-1989	Medicine
University Department of Medicine, Glasgow University	MRCP	1989-1993	Internal Medicine
Beatson Institute for Cancer Research, UK	PhD	1993-1997	Molecular Biology
Beatson Oncology Center, Glasgow University, Glasgow, UK	MSc	1997-2000	Medical Oncology

### **Positions and Honors:**

1989-1993	JHO/SJO, University Department of Medicine, University of Glasgow, Scotland UK.
1993-1996	Cancer Research Campaign PhD Research Scholarship, Beatson Institute for Cancer Research, Glasgow, UK.
1996-2000	Specialist Registrar, Medical Oncology, Beatson Oncology Center, Glasgow, UK.
2000-2001	Senior Fellow, Institute for Drug Development, The University of Texas Health Science Center, San Antonio.
2002-2003	Doris Duke Charitable Foundation Clinician-Scientist, Faculty Member, Institute for Drug Development, Texas
2003-Today	The Institute of Cancer Research and Royal Marsden Hospital.
1989	MB ChB Glasgow University (with merits and distinctions).
1993	Member of the Royal College of Physicians (MRCP, UK)
1993-1998	Cancer Research Campaign PhD Clinical Research Fellowship.
1997	PhD: 'Macrophage Inflammatory Protein-1 $\alpha$ : An Inhibitor of Epidermal Keratinocyte Proliferation.'
1997-1999	Medical Research Council Grant: "Investigating the Role of MIP-1 $\alpha$ in Epidermal Proliferation <i>in vivo</i> in MIP-1 $\alpha$ knockout mice." (\$40,000 per annum).
1997-2000	MSc: Masters degree in Oncology (with Distinction).
1999	AACR/ ASCO/ FECS Scholarship to attend the first 'Methods in Clinical Cancer Research Workshop' at Flims.
1998	Royal College of Physicians Traveling Fellowship to work at the SWOG statistical headquarters at the Fred Hutchinson Cancer Center, Seattle (Drs J Crowley, S. Green and J. Benedetti).
1999	Awarded Advanced Translational Fellowship in Anti-Cancer Drug Development (Institute for Drug Development, Cancer Therapy and Research Center, UTHSCSA, San Antonio, TX, USA).
2000	Berlex Oncology Foundation Award to attend workshops on clinical trial design and statistics.
2001	ASCO Merit Award: Phase I, Pharmacokinetic, and Pharmacodynamic Trial of <i>Bcl-2</i> Antisense and Docetaxel in Hormone-Refractory Prostate Cancer (\$1,500).
2001	ASCO Young Investigator Award (\$35,000). "Inhibiting Epidermal Growth Factor Receptor (EGFR) Signaling in Metastatic Breast Carcinoma with ZD1839 and Determining Biological Correlates of Activity"
2001	Berlex Oncology Foundation Award (\$10,000 to attend workshop on pharmacokinetics and pharmacogenetics).
2002-2006	Doris Duke Clinician Scientist Career Development Award (Personal Award; \$108,000 per annum for 5 years).
2002-2004	NIH R21 Quick Trials Grant (Overcoming Barriers in Early Clinical Trials) \$325,000 dollars per annum (P.I.).
2002-2004	Mesothelioma Applied Research Foundation grant to study the pharmacogenetics of Alimta (\$100,000, P.I.).
2003	FRCP (Glasgow), elected to the Fellowship of the Royal College of Physicians and Surgeons of Glasgow.
2004	FRCP (London), elected to the Fellowship of Royal College and Physicians, London, July 2005
2006	Awarded Prostate Cancer Research Foundation grant; £100,000
2006-2008	Elected Member as ESMO National Representative for the UK
2006	Awarded MRC early clinical trials grant; £590,000
2007	MRC Biomarker Grant (£1.2 million) to study circulating tumours cells in advanced prostate cancer (PI).
2007	ECMC Funding awarded ((£2.5 million over 5 years; co-investigator)
2006	Awarded Prostate Cancer Research UK grant £50,000
2006	Elected Member of the NCRI Prostate Cancer Clinical Studies Group
2007	AACR-NCI-EORTC Elected Member of the Scientific Committee
2008	Cancer Research UK, Serving member of the New Agents Committee
2009-2011	Member of Society for Translational Oncology
2009	Appointed position of Reader in Experimental Cancer Medicine from Senior Lecturer (10/9/2009)
2010	Conferred title of Professor in Experimental Cancer Medicine
2010	Editorial Board Member: Journal of Clinical Oncology, Molecular Cancer Therapeutics, European Journal of Cancer and The Oncologist.

2010	Cancer Research UK, serving member on the Bursaries Committee.
2011	Cancer Research UK, serving member on the Clinical Scientist Appointment Committee.
2011	AACR Scientific Program Committee
2011	Invited to serve as member of the AACR Special Conferences Committee to April 2014.
2011	Information Governance training completed 27 June 2011
2011	Appointed by AACR to serve as a Scientific Editor for Cancer Discovery focusing on Research Watch . Jan 2011 to Dec 2013
2012	ASCO Education Committee.
2012	European Male Urology Conference (EMUC) Organizing Committee.
2011	September 25, to receive the ESMO Award at the 36 <sup>th</sup> ESMO Annual congress in Stockholm
2012	Appointed as Scientific Chair for ESMO Madrid 2014 (January 2012)
2012	AACR Team Science Award
2012	Employment Law Training 3 May 2012
2012	Elected Member Fellow of the Academy of Medical Sciences (FMedSci)
2012	Certified updated GCP training.
2014	London Movember Centre of Excellence for Prostate Cancer, Centre Director

### SELECTED PEER-REVIEWED PUBLICATIONS:

1. Muir KW, Rodger JC, **de Bono JS**, Irving JB. Drugs and the Exercise Test. *British Medical Journal* 1992. 305 (6857): 808-9.
  2. Muir KW, Rodger JC, **de Bono JS**, McDonald H, Irving JB. A Survey of Exercise Testing Practice in Scottish Hospitals. *Scottish Medical Journal* 1993. 38(2): 45-7.
  3. Twelves CJ, Gardner C, Flavin A, Sludden J, Dennis I, **de Bono JS**, Judson, NM Bleehen. Phase I And Pharmacokinetic Study Of DACA - A Novel Inhibitor Of Topoisomerase I And II. *British Journal of Cancer*, 1999. 80 (11): 1786-1791.
  4. Jarmin DI, Nibbs RJ, Jamieson T, **de Bono JS**, Graham GJ. GM-CSF and IL-3 regulate chemokine and chemokine receptor expression in bone marrow macrophages. *Experimental Haematology* 1999, 27 (12): 1735-1745.
  5. **de Bono JS**, Lee F, Simpson A, Naik S, Soukop M, Dunlop DJ. Metastatic Extragonadal Seminoma Associated With Cardiac Transplantation. *Annals of Oncology* 2000. 11(6): 749-52.
  6. **de Bono JS**, Dalglish AG, Carmichael J, Diffley J, Lofts FJ, Fyffe D, Ellard S, Evans TRJ. Phase I Study of ONO-4007, A Synthetic Analogue Of The Lipid A Moiety Of Bacterial Lipopolysaccharide. *Clinical Cancer Research* 2000. 6(2): 397-405.
  7. **de Bono JS**, Simpson A, Paul J, Kirk D, Underwood M, Graham J, Kaye SB. Improving The Outcome Of Salvage Treatment For Relapsed Non Seminomatous Germ Cell Tumours (NSGCT). *British Journal of Cancer* 2000. 83(4): 426-30.
  8. **de Bono JS**, Twelves C. The Oral Fluorinated Pyrimidines. *Investigational New Drugs*. (19: 41-59, 2001).
  9. Evans T, Anthony A, **de Bono JS**. Vitamin D analogues in cancer therapy. *Current Topics in Steroid Research* 2000, 3:89-95).
  10. Fizazi K, Tjulandin S, Salvioni R, Ragan D, Bokemeyer C, Gerl A, **de Bono JS**, Fléchon A, De Giorgi U, Kerbrat P, Geoffrois L, Bower M, Mahe C, Bouzy J, Bulanov A, Pizzocarro G, Hartmann JT, Nichols C, Fossa S, Droz JP. Viable Malignant Cells After Primary Chemotherapy For Metastatic Non- Seminomatous Germ-Cell Tumors (NSGCT): Results From An International Study. *Journal of Clinical Oncology*, 2001. 19: 2647-2657.
  11. Evans TRJ, Colson KW, Lofts FJ, Cunningham D, Anthoney DA, Gogas H, **de Bono JS**, Menday P, Mansi JL. A Phase II trial of the vitamin D analogue EB1089 in patients with inoperable pancreatic cancer. *British Journal of Cancer*. 86(5):680-685, 2002.
  12. **de Bono JS**, Stephenson J Jnr, Baker SD, Hidalgo M, Patnaik A, Eckhardt SG, Hammond L, Diab S, Von Hoff DD, Rowinsky E. Phase I And Pharmacokinetic Study Of Troxacitabine (BCH-4556): A Novel Nucleoside Analogue With The Unnatural L-Enantiomer Configuration. *Journal of Clinical Oncology* 20: 1: 96-109, 2002.
  13. Propper DJ, **de Bono JS**, Ellard S, Flanagan E, Bates N, Levitt NC, Smith P, Ganesan TS, Talbot DC, Harris AL, Twelves CJ. A Phase I Study Of XR5000 (DACA) by 120 Hour Intravenous Infusion. *Journal of Clinical Oncology*, 21 (2):203-210, 2003
  14. **de Bono JS**, Rowinsky EK. Targeting Signal Transduction: The erbB family as a target for therapeutic development against cancer. *Trends in Molecular Medicine*, 8 (4): S19-S26, 2002.
  15. **de Bono JS**, Rowinsky EK. Signal Transduction Inhibition for the Treatment of Colorectal Cancer. *British Medical Bulletin*. 2002;4:227-54.
  16. Pentheroudakis G, **de Bono JS**, Kaye SB, Simpson A, Paul J, Brown I, Parmenter B, Kirk A, Vasey P, Raby N, Kirk D. Improved prognosis of patients with intermediate and poor risk non-seminomatous germ cell tumours through the optimization of combined modality treatment. *British Journal of Urology* 2003 Jul; 92 (1) 43-46
-

17. Parmenter B, **de Bono JS**, Brown IL, Nandini M, Kirk D. Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. *British Journal of Urology*, 2003 Jul 92 (1): 43-46
  18. Tolcher A, Ochoa L, Hammond L, Patnaik A, Edwards T, Takimoto C, Smith L, **de Bono JS**, Schwartz G, DeWitte M, Martino H, Chari R, Lambert J, E Rowinsky. Cantuzumab Mertansine, A Maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic and biologic correlative study. *Journal of Clinical Oncology*, 21(2):211-22, 2003.
  19. **de Bono JS**, Tolcher AW, Rowinsky EK. Treating Patients with Metastatic Breast Carcinoma with the Farnesyltransferase Inhibitors. *Seminars in Oncology*. 2003 Oct; 30 (5 Suppl 16): 79-92.
  20. **de Bono JS**, Tolcher AW, Rowinsky EK. What is the future of cytotoxic chemotherapy for the treatment of breast cancer: Selective cytotoxicity based on biology is the key. *Breast Cancer Research* 2003;5(3) 154-9
  21. Benson C, Kay S, Workman P, Garrett, Walton M, **de Bono JS**. Clinical anticancer drug development: targeting the cyclin dependent kinases. *Br J Cancer* (2005) 92, 7-12
  22. **de Bono JS**, Rha SY, Stephenson J, Schultes BC, Munroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular anti-tumor immunity. *Annals of Oncology* 15: 1825-1833; 2004
  23. **de Bono JS**, Tolcher AW, Forero A, Vanhove GFW, Takimoto C, Bauer RJ, Hammond LA, Patnaik A, White ML, Shen S, Khazaeli MB, Rowinsky EK, LoBuglio A. Pharmacokinetics, tolerability and biodistribution of ING-1, a Human-Engineered™ monoclonal antibody to Ep-CAM in patients with advanced adenocarcinomas. *Clinical Cancer Research* 2004, 10(22):7555-65
  24. Calvo E, Tolcher AW, Hammond LA, Patnaik A, **de Bono JS**, Eiseman IA, Olson SC, Lenehan PF, Rowinsky EK. Administration of CI-1033, An Irreversible PAN-erbB tyrosine Kinase Inhibitor, is Feasible on a 7-Day On, &-Day Off Schedule: A Phase I Pharmacokinetic, and Food Effect Study. *Clinical Cancer Research* 2004. 10(21):7112-20
  25. Attard G, **de Bono JS**. The Changing Face of Cancer Therapeutics: Improved Outcome and Decreased Toxicity with Molecular Targeted Drugs. *Malta Medical Journal* Vol 16 Iss 02 July 2004
  26. Vidal L, Attard G, Kaye S, **de Bono JS**. Reversing Resistance To Targeted Therapy. *J Chemother*. 2004 Nov;16 Suppl 4:7-12. Review
  27. Bissett D, Cassidy J, **de Bono JS**, Muirhead F, Main M, Robson L, Fraier D, Magne ML, Pellizzoni C, Porro MG, Spinelli R, Speed W, Twelves C. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148) : a polymeric derivative of camptothecin (CPT). *Br J Cancer* 2004 July 5;91(1):50-5
  28. Attard G, Gilbert D, de Bono JS Can the outcome of patients with castration refractory prostate cancer be improved through rational drug development? *Urological Cancer Abstracts* . Review Issue No 22 Spring 2005 ISSN 1461-3328
  29. Attard G, Greystoke A, Kaye SB, **de Bono JS**. Update on Tubulin Binding Agents. *Pathol Biol (Paris)*. 2006 Mar; 54 (2):72-84. Review.
  30. Attard G, Beldegrun A, **de Bono JS**. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. *Br J Urol S* 2005; 96, 1241-1246.
  31. Blagden S, **de Bono JS**. Drugging cell kinases in Cancer therapy. *Curr Drug Targets* 2005 May;6(3):325-35.
  32. Kristeleit R, Fong P, Aherne W, **de Bono JS**. Histone Deacetylase Inhibitors: Emerging anticancer Therapeutic Agents? *Clin Lung Cancer*. 2005 Sep;7 Suppl 1:S19-30.
  33. Vidal L, Blagden S, Attard G, **de Bono JS**. Making sense of antisense. *Eur J Cancer* 2005, 41:2812-2818
  34. Rowinsky EK, Beeram M, Hammond L, Schwartz G, **de Bono JS**, Forouzesh B, Chu Q, Drengler R, Latz JE, John W, Nguyen B. A phase I and pharmacokinetic study of pemetrexed plus ironotecan in patients with advanced solid malignancies. *Clin Cancer Res*. 2007 Jan 15;13(2):532-9
  35. Greystoke A, Blagden S, Attard G, Molife R, Vidal L, **de Bono JS**, Steward W. A phase I study intravenous TZT-1027 administered on a day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 8 alone in patients with advanced solid tumours. *Ann Oncol*. 2006 Aug;17(8):1313-9. Epub 2006 May 25.
  36. Benson C, White J, **de Bono JS**, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Frenz L, Rose F, Walton M, Workman P, Kaye S, Gianella-Borradori, Twelves C, Judson I. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202;R-Roscovitine), administered twice daily for 7-days every 21 days. *Br J Cancer*. 2007 Jan 15;96(1):29-37. Epub 2006 Dec 19.
  37. Mita MM, Rowinsky EK, Forero L, Izbicka E, Rizzo J, Eckhart G, Weiss GR, Berrem M, Mita AC, **de Bono JS**, Tolcher AW, Hammond LA, Berg K, Takimoto C, Patnaik A. A Phase II, pharmacokinetic, and biologic study of Semaxanib and Thalidomide in patients with metastatic melanoma. *Cancer Chemother Pharmacol*. 2007 Feb;59(2):165-74. Epub 2006 May 31.
-

38. Lee CP, de Jonge MJA, O'Donnell A, Schothorst K, Hanwell J, Chick J, Adams L, Drolet DW, **de Bono JS**, Kaye SB, Judson IR, Verweij J. A Phase I study of a new nucleoside analogue, OSI-7836, using two administered schedules in patients with advanced solid malignancy. *Clin Cancer Res*. 2006 May 1;12(9):2841-8.
  39. Mita AC, Hammond LA, Bonate PL, Weiss G, McCreery H, Syed S, Garrison M, Chu QSC, **de Bono JS**, Jones CB, Weitman S, Rowinsky EK. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for three weeks every 28-days in patients with advanced solid tumors. *Clin Cancer Res*. 2006 Sep 1;12(17):5207-15.
  40. Tolcher AW, Hao D, **de Bono JS**, Miller A, Patnaik A, Hammond LA, Smetzer L, Van Wart Hood J, Merritt J, Rowinsky EK, Takimoto C, Von Hoff D, Eckhardt SG. A Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered advexin®, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. *J Clin Oncol*. 2006 May 1;24(13):2052-8
  41. Attard G, **de Bono JS**, Parker C, Horwich A. Management strategies for hormone-refractory prostate cancer. *Am J Cancer*. 5(3):163-169, 2006
  42. Legge F, Eaton D, Molife R, Ferrandina G, Judson I, **de Bono JS**, Kaye S. Participation of patients with gynecological cancer in phase I clinical trials: two years experience in a major cancer center. *Gynecol Oncol*. 2007 Mar;104(3):551-6. Epub 2006 Oct 24.
  43. Attard G, Sarker D, Reid A, Parker C, **de Bono JS**. Improving the outcome of patients with castration refractory prostate cancer through rational drug development. *Br J Cancer* 2006 Oct 95 (7) 767-74
  44. Hammond L, Thomas M, Beeran M, Iwasaki M, Abbruzzese, Lassere Y, Meyers C, Hoff, P, Patnaik A, **de Bono JS**, Norris J, Hitoshi M, Mita A, Rowinsky E. Phase I and Pharmacokinetic (PK) trial of 3'-C-Ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I,II and III in patients with advanced solid malignancies . *Clin Cancer Res*. 2007 Jan 15;13(2 Pt 1):532-9.
  45. **de Bono JS**, Bellmunt J, Attard G, Droz J-P, Miller K, Flechon A, Steinberg C, Parker C, Zugmaier G, Gimenez V, Cockey L, Mason M, Graham J. An Open Label Phase II Study to Evaluate the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naïve Patients with Hormone Refractory Prostate Cancer. *J Clin Oncol*. 2007 Jan 20;25(3):257-62..
  46. Reid A, Vidal L, Shaw H, **de Bono JS**. Inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). *Eur J Cancer*. 2007 Feb;43(3):481-9. Epub 2007 Jan 8.
  47. Takimoto C, Hammond L, Latz J, Forero L, Beeram M, Forouzes B, **de Bono JS**, Tolcher A, Patnaik A, Monroe P, Woods L, Schneck K, Clark R, Rowinsky E. Phase I and pharmacokinetic study of pemetrexed with high dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. *Clin Cancer Res* 2007;13(9) 2675-2683
  48. Molife R, Fong P, Scurr M, Judson I, Kaye S, **de Bono JS**. HDAC Inhibitors and Cardiac Safety. *Clin Cancer Res*. 2007 Feb 1;13(3):1068; author reply 1068-9.
  49. Yap TA, Molife LR, Blagden SP, **de Bono JS**. Targeting cell cycle kinases and kinesins in anticancer drug development. *Expert Opinion Drug Discovery* 2007 2 (4)
  50. Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz R-M, Thompson J, Selby P, **de Bono JS**, Melcher A, Pandha H, Coffey M, Vile R, Harrington K. Cyclophosphamide Facilitates Anti-Tumor Efficacy Against Subcutaneous Tumors Following Intravenous Delivery of Reovirus. *Clin Cancer Res* 2008 Jan 1;14(1):259-69.
  51. **de Bono JS**, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connelly M, Terstappen LWMM, Gualberto A. Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-1 Receptor. *Clin Cancer Res* 2007;13(12) 3611-3616
  52. Attard G and **de Bono JS**. Letter in reply to Menendez and Lupu. *Journal of Clinical Oncology* 2007.11.2499
  53. Jhavar S, Reid A, Clark J, Kote-Jarai Z, Christmas T, Thompson A, Woodhouse C, Ogden C, Fisher C, Corbishley C, **de Bono JS**, Eeles R, Brewer, D, Cooper C. Detection of *TMPRSS2-ERG* translocations in human prostate cancer by expression profiling using Genechip Human Exon 1.0 ST arrays. *J Mol Diagn*. 2008 Jan;10(1):50-7. Epub 2007 Dec 28.
  54. Yap TA, Harris D, Barriuso J, Wright M, Riisnaes R, Clarke J, Ledaki I, Savage R, Chen R, **de Bono JS**. Phase I trial to determine the dose range for the c-Met inhibitor ARQ197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a-day schedule. *J Clin Onc*. 26(15) 20 May 2008.
  55. Attard G, Kitzen J, Blagden SP, Fong PC, Pronk LC, Zhi J, Zugmaier G, Verweij J, **de Bono JS**, de Jonge M. A phase 1b study of pertuzumab, a recombinant humanized antibody to HER2, and docetaxel in patients with advanced solid tumours. *Br J Cancer* 2007; 97 (10) 1338-1343.
-

56. Steele NL, Plumb JA, Vidal L, Tørnelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Jeffry –Evans TR, **de Bono JS**. Phase I, pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat (PXD101) in patients with advanced solid tumors. *Clin Cancer Res* 2008 Feb 1;14(3):804-10.
  57. Vidal L, Pandha HS, Yap TA, White CL, Twigger KR, Vile RG, Melcher A, Coffey M, Harrington KJ, **de Bono JS**. A phase I study of intravenous oncolytic Reovirus Type 3 Dearing in patients with advanced cancer. *Clin Cancer Res* 2008 Nov 1;14(21):7127-37
  58. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, **de Bono JS**. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. *Clin Cancer Res*. 2007;13(19):5834-40
  59. Clark J, Attard G, Jhavar S, Flohr P, Reid A, **De-Bono J**, Eeles R, Scardino P, Cuzick J, Fisher G, Parker MD, Foster CS, Berney D, Kovacs G, Cooper CS. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. *Oncogene*. 2008 Mar 27;27(14):1993-2003. Epub 2007 Oct 8. PubMed PMID:17922029.
  60. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, Calvert H, **de Bono JS**. Phase I and pharmacokinetic study of lextatumumab in patients with advanced cancers. *Clin Cancer Res*. 2007 Oct 15;13(20):6187-94.
  61. Chu QS, Schwartz G, **de Bono JS**, Smith DA, Koch KM, Versola MJ, Pandite L, Arya N, Curtright J, Fleming RA, Ho PT, Rowinsky EK. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. *J Clin Oncol*. 2007 Aug 20;25(24):3753-8.
  62. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, **de Bono JS**, Scardino P, Cuzick J, Cooper CS; Transatlantic Prostate Group. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. *Oncogene*. 2008 Jan 10;27(3):253-63. Epub 2007 Jul 16.
  63. Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P, Reid A, Edwards S, Kovacs G, Berney D, Foster C, Massie CE, Fletcher A, **De Bono JS**, Scardino P, Cuzick J, Cooper CS; Transatlantic Prostate Group. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. *Br J Cancer*. 2008 Jul 22;99(2):314-20. Epub 2008 Jul 1. PubMed PMID: 18594527; PubMed Central PMCID: PMC2480965.
  64. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatee S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, **de Bono JS**. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. *J Clin Oncol*. 2008 Oct 1;26(28):4563-71. Epub 2008 Jul 21
  65. Yap TA, Carden CP, Attard G, **de Bono JS**. Targeting CYP17: established and novel approaches in prostate cancer. *Curr Opin Pharmacol*. 2008 Aug;8(4):449-57. Epub 2008 Jul 28. Review. PubMed PMID: 18619560.
  66. Scott EN, Thomas AL, Molife LR, Ahmed S, Blagden Sm, Fong P, Kowal K, McCoy C, Wiesinger H, Steward W, **de Bono J**. A Phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours. *Cancer Chemother Pharmacol*. 2009 Jul;64(2):425-9. Epub 2009 Mar 12. PubMed PMID: 19280191.
  67. Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, Reid AH, A'Hern R, Fong PC, Oommen NB, Molife R, Dearnaley D, Parker C, Terstappen LW, **de Bono JS**. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. *Ann Oncol*. 2009 Jan;20(1):27-33. Epub 2008 Aug 11. PubMed PMID: 18695026.
  68. Shepherd CJ, Rizzo S, Ledaki I, Davies M, Brewer D, Attard G, **de Bono JS**, Hudson DL Expression profiling of CD133(+) and CD133(-) epithelial cells from human prostate. 2008; *The Prostate*, 68 (9). pp. 1007-1024. ISSN 0270-4137
  69. Appels NM, Bolijn M J, Chan K, Stephens T C, Hochtin-Boes G, Middleton M, Beijnen JH, **de Bono JS**, Harris AL, Schellens JHM. Phase I pharmacokinetic and pharmacodynamic study of the prenyltransferase inhibitor AZD3409 in patients with advanced cancer. 2008 *Br J Cancer* 98 (12). pp. 1951-1958. ISSN 0007-0920.
  70. White CL, Twigger K R, Vidal L, **de Bono JS**, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG , Melcher AA, Pandha, HS, Harrington KJ. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. 2008 *Gene Therapy* 15 (12). pp. 911-920. ISSN 0969-7128.
  71. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, **de Bono JS**, Selby P, Coffey M, Vile R, Melcher A. Reovirus activates human dendritic cells to promote innate antitumor immunity. 2008; *Journal of Immunology* 180 (9). pp. 6018-6026. ISSN 0022-1767
  72. Talbot DC, Davies J, Callies S, Andrea V, Lahn M, Ang J, **de Bono JS**, Ranson M. First human dose study evaluating safety and pharmacokinetics of LY218308, an antisense oligonucleotide designed to inhibit surviving. *J Clin Onc* 26 (15) 20 May 2008.
-

73. Karavasilis V, Digue L, Arkenau H-T, Eaton D, Stapleton S, **de Bono JS**, Judson I, Kaye S. Identification of factors limiting patient recruitment into phase I trials: A study from the Royal Marsden Hospital. 2008; *European Journal of Cancer* pp. 978-982. ISSN 0959-8049
  74. Banerji U, **de Bono JS**, Judson I, Kaye S, Workman P. Biomarkers in early clinical trials: The committed and the skeptics. [Letter]. 2008 *Clin Can Res*(8). pp. 2512-2513. ISSN 1078-0432
  75. Blagden SP, Molife LR, Seebaran A, Payne M, Reid, AHM, Protheroe AS, Vasist LS, Williams DD, Bowen C, Kathman SJ, Hodge JP, Dar MM, **de Bono JS**, Middleton MR. A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. 2008 *Br J Cancer* 98 (5). pp. 894-899. ISSN 0007-0920
  76. Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox ja, Heise C, Louie S, Aziz N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, **de Bono JS**. A phase I pharmacokinetic and pharmacodynamic study of TK1258 an oral, multi-targeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. *Clin Cancer Research* 2008 April 1; 14 (7): 2075-81.
  77. Comins C, Heinemann L, Harrington K, Melcher A, **De Bono J**, Pandha H. Reovirus: viral therapy for cancer 'as nature intended'. *Clin Oncol (R Coll Radiol)*. 2008 Sep;20(7):548-54. Epub 2008 Jun 25. Review. PubMed PMID: 18583112.
  78. Twigger K, Vidal L, White CL, **de Bono JS**, Bhide S, Coffey M, Thompson B, Vile RG, Heinemann L, Pandha HS, Errington F, Melcher AA, Harrington KJ. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. 2008 *Clin Cancer Res* 14 (3). pp. 912-923. ISSN 1078-0432
  79. Carden CP, Olmos D, **de Bono JS**. Validated and Qualified Biomarkers Are Critical to Optimizing Anticancer Drug Development: Potential Roles for the Study of Circulating Tumor Cells. In: UNSPECIFIED, (ed.) *American Society of Clinical Oncology 2008 Educational Book*. American Society of Clinical Oncology, pp. 166-170.
  80. Arkenau HT, Olmos D, Ang JE, **de Bono JS**, Judson I, Kaye S. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. 2008 *Br J Cancer* 98 (6). pp. 1029-1033. ISSN 0007-0920
  81. Sarker D, Molife LR, Evans, TRJ, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S, Aziz, N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, **de Bono JS**. A phase I pharmacokinetic and pharmacodynamic study of TK 1258, an oral, multi-targeted receptor tyrosine kinase inhibitor in patients with advanced solid tumour. *Clin Cancer Res*. 2008 Apr 1;14(7):2075-81
  82. Olmos D, Okuno S, Schuetze SM, Paccagnella ML, Yin D, Gualberto A, Worden Fpm Haluska P, **de Bono JS**, Scurr M. Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. *J. Clin Onc* 26 (15) 20 May 2008.
  83. Langenberg M, van Herpen CM, **de Bono JS**, Unger C, Schellend JH, Hoekman K, Blum HE, Le Maulf F, Fielding A, Voest EE. Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: A randomized phase II study of cediranib. *J Clin Onc* 26 (15) 20 May 2008.
  84. **de Bono JS**, Attard G, Reid AH, Parker C, Dowsett M, Molife R, Yap TA, Molina A, Lee G, Dearnaley D. Anti-tumor activity of abiraterone acetate (AA), a CYP 17 inhibitor of androgen synthesis, in chemotherapy naïve and docetaxel pre-treated castration resistant prostate cancer (CRPC). *J Clin Onc* 26 (15) 20 May 2008.
  85. Fong PC, Boss DS, Carden CP, Roelvink M, De Greve J, Gourley CM, Carmichael J, **de Bono JS**, Schellens JH Kaye SB. AZD 2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer. Results from a phase I study. *J Clin Onc* 26 (15) 20 May 2008
  86. Attard C, Olmos D, Arkenau HT, Ledaki, Carden CP, Reid AH, Ang J, Fong PC, Parker C, **de Bono JS**. Post and post treatment circulating tumor cell counts (CTCs) and overall survival 9OS) in castration-resistant prostate cancer 9CRPC): the Royal Marsden Hospital (RMH) experience. *J Clin Onc* 26 (15) 20 May 2008
  87. Ang J, Arkenau H, Olmos D, Barriuso J, Ashley S, Little A, Pacey S, **de bono JS**, Judson I, Kaye SB. 90-day mortality rate in cancer patients treated with the context of phase I trials: Can we identify patients who should not go on trial? *J Clin Onc* 26 (15) 20 May 2008
  88. Postel-Vinay SC, Arkenau H Ashley S, Barriuso J, Olmos D, Shaw H, Wright M, Judson I, **de Bono JS**, Kaye SB. Clinical benefit in phase I trials of novel molecularly targeted agents: Does dose matter? *J Clin Onc* 26 (15) 20 May 2008
  89. Carden CP, Raynaud FI, Jones RL, Riggs SB Martins V, Oommen N, McIntosh D, Lee G, **de Bono JS**, Kabbinar FF. Crossover pharmacokinetics (PK) study to assess oral administration of abiraterone acetate capsule and tablet formulations in fasted and fed states in patients with prostate cancer. *J Clin Onc* 26 (15) 20 May 2008.
  90. **de Bono JS**, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, Shaw H, Workman P, Kaye S, Rowinsky E, Aherne W, Atadja P, Scott JW, Amita Patnaik, Mita M. Phase I pharmacokinetic and pharmacodynamics study of LAQ824 a hydroxamate histone deacetylase inhibitor with HSP90 inhibitory profile in patients with advanced solid tumors. *Clin Cancer Res* 2008 Oct 15;14(20):6663-73.
-

91. Attard G, Ang JE, Olmos D, **de Bono JS**. Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development. *J Clin Pathol*. 2008 Aug;61(8):891-6. Epub 2008 May 21. Review. PubMed PMID: 18495790.
  92. **de Bono JS**, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LWW, Pienta KJ, Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration resistant prostate cancer. *Clin Cancer Res* 2008 Oct 1;14(19):6302-
  93. Olmos D, Swanton C, **de Bono JS**. Targeting Polo-Like Kinase: Learning too little too late? *J Clin Oncol*. 2008 Dec 1;26(34):5497-9. Epub 2008 Oct 27
  94. Molife LR, Attard G, Fong PC, Karavasilis V, Reid AHA, Patterson S, Riggs CE Jr, Higano C, Stadler WM, McCulloch W, Dearnaley D, Parker C, **de Bono JS**. Phase II, two-stage, single arm trial of histone deacetylase inhibitor (HDACi) Romidepsin in metastatic castration resistant prostate cancer (CRPC). *Ann Oncol*. 2010 Jan;21(1):109-13. Epub 2009 Jul 16.
  95. Workman P, **de Bono JS**. Targeted therapeutics for cancer treatment: Major progress towards personalized molecular medicine. *Current Opinion in Pharmacology*. *Curr Opin Pharmacol*. 2008 Aug;8(4):359-62. Epub 2008 Aug 21.
  96. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, **de Bono JS**. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. *Cancer Res*. 2009 Apr 1;69(7):2912-8. PubMed PMID: 19339269.
  97. Carden CP, Banerji U, Kaye SB, Workman, **de Bono JS**. From darkness to light with biomarkers in early clinical trials. *Clinical Pharmacology and Therapeutics* 2009 85:2; 131-131
  98. Arkenau HT, Brunetto AT, Barriuso J, Olmos D, Eaton D, **de Bono J**, Judson I, Kaye S. Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer. *Oncology*. 2009;76(3):151-6. Epub 2009 Jan 23. PubMed PMID: 19169046.
  99. Reid AH, Attard G, Barrie E, **de Bono JS**. CYP17 inhibition; novel hormonal therapeutic strategies for prostate cancer. *Nat Clin Pract Urol*. 2008 Nov;5(11):610-20
  100. Scher HI, Jia X, **de Bono JS**, Fleisher M, Pienta KJ, Raghavan D, Heller G. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. *Lancet Oncol*. 2009 Mar;10(3):233-9. Epub 2009 Feb 11.
  101. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, **de Bono JS**, Gualberto A, Hammer GD. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. *Cancer Chemother Pharmacol*. 2010 Mar;65(4):765-73. Epub 2009 Aug 2. PubMed PMID: 19649631; PubMed Central PMCID: PMC2875253.
  102. Ang JE, Olmos D, **de Bono JS**. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. *Br J Cancer*. 2009 Mar 10;100(5):671-5. Epub 2009 Feb 17. Review. PubMed PMID: 19223900; PubMed Central PMCID: PMC2653756.
  103. Sarker D, Reid AH, Yap TA, **de Bono JS**. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. *Clin Cancer Res*. 2009 Aug 1;15(15):4799-805. Epub 2009 Jul 28. Review. PubMed PMID: 19638457.
  104. Attard G, Reid AH, Olmos D, **de Bono JS**. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. *Cancer Res*. 2009 Jun 15;69(12):4937-40. Epub 2009 Jun 9. Review. PubMed PMID: 19509232.
  105. Rodon J, Garrison M, Hammond LA, **de Bono J**, Smith L, Forero L, Hao D, Takimoto C, Lambert JM, Pandite L, Howard M, Xie H, Tolcher AW. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. *Cancer Chemother Pharmacol*. 2008 Oct;62(5):911-9. Epub 2008 Feb 27. PubMed PMID: 18301896.
  106. Baird R, Kitzen J, Clarke P, Planting A, Reade S, Reid A, Welsh L, Zaro LP, de las Heras B, Judson I, Kaye S, Eskens F, Workman P, **de Bono JS**, Verweij J. Phase I Safety, Pharmacokinetic and Pharmacogenomic Trial of ES-285, a Novel Marine Cytotoxic Agent, Administered to Adult Patients with Advanced Solid Tumors. *Mol Cancer Ther*. 2009 Jun;8(6):1430-7. Epub 2009 Jun 9.
  107. Plummer R, Vidal L, Griffin M, Lesley M, **de Bono JS**, Coulthard S, Sludden J, Siu, LL, Chen EX, Oza AM, Reid GK, McLeod R, Besterman JM, Lee C, Judson I, Calvert H, Boddy AV. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. *Clin Cancer Res*. 2009 May 1;15(9):3177-83. Epub 2009 Apr 21
  108. Langenberg MH, van Herpen CM, **De Bono J**, Schellens JH, Unger C, Hoekman K, Blum HE, Fiedler W, Drevs J, Le Maulf F, Fielding A, Robertson J, Voest EE. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. *J Clin Oncol*. 2009 Dec 20;27(36):6152-9. Epub 2009 Nov 9. PubMed PMID: 19901116.
-

109. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, **de Bono JS**. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med*. 2009 Jul 9;361(2):123-34. Epub 2009 Jun 24
110. Postel-Vinay S, Arkenau H-T, Olmos D, Ang J, Barriuso J, Ashley A, Banerji U, **de Bono JS**, Judson I, Kaye SB. Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? *Br J Cancer* (2009) 100, 1373-1378
111. Reid A H & **de Bono JS**. Molecular characterization of ERG, ETV1- and PTEN-gene loci identifies patients at low and high risk of death from prostate cancer. *Br J Cancer*. 2010 Feb 16;102(4):678-84. Epub 2010 Jan 26.
112. Mita AC, Denis LJ, Rowinsky EK, **de Bono JS**, Goetz AD, Ochoa L, Forouzes B, Beeram M, Patnaik A, Molpus K, Semiond D, Besenval M, Tolcher AW. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A; Cabazitaxel), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. *Clin Cancer Res*. 2009 Jan 15;15(2):723-30.
113. Attard G, **de Bono JS**. Prostate cancer: PSA as an intermediate end point in clinical trials. *Nat Rev Urol*. 2009 Sep;6(9):473-5. No abstract available. PMID: 19727145
114. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J-E, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, **de Bono JS**, Plummer R. Phase I trial of the irreversible ErbB1 (EGFR) and ErbB2 (HER2) kinase inhibitor BIBW 2992 in patients with advanced solid tumors. *J Clin Oncol*. 2010 Sep 1;28(25):3965-72. Epub 2010 Aug 2.
115. Attard G, Cooper C, **de Bono JS**. Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break? *Cancer Cell*. 2009 Dec 8;16(6):458-62.
116. Attard G, **de Bono JS**, Clark J, Cooper CS. Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies. *Clin Cancer Res*. 2010 Feb 15;16(4):1340.
117. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, **de Bono JS**, Haluska P. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. *Lancet Oncol*. 2010 Feb;11(2):129-35. Epub 2009 Dec 23. PubMed PMID: 20036194; PubMed Central PMCID: PMC2941877.
118. Sandhu, SK, Yap TA, **de Bono JS**. Poly (ADP-Ribose) Polymerase Inhibitors in Cancer Treatment. A Clinical Perspective. *Eur J Cancer*. 2010 Jan;46(1):9-20. Epub
119. Carden CP, Molife LR, **de Bono JS**. Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor. *Mol Can Ther*. 2009 Aug;8(8):2077-8. Epub 2009 Aug 11
120. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkard E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, **de Bono JS**. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. *J Clin Oncol*. 2009 Aug 10;27(23):3742-8. Epub 2009 May 26. PubMed PMID: 19470933.
121. Lal R, Harris, Postel-Vinay S, **de Bono JS**. Reovirus: Rationale and clinical update. *Current Opinion Mol Ther* 2009, 11 (5): 532-539
122. Yap TA, Garrett MD, Walton MI, Raynaud F, **de Bono JS**, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. *Curr Opin Pharmacol*. 2008 Aug;8(4):393-412. Epub 2008 Aug 27.
123. Tan DS, Thomas GV, Garrett MD, Banerji U, **de Bono JS**, Kaye SB, Workman P. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. *Cancer J*. 2009 Sep-Oct;15(5):406-20.
124. Shan L, Ambrosine L, Clark J, Yáñez-Muñoz RJ, Fisher G, Kudahetti SC, Yang J, Kia S, Mao X, Fletcher A, Flohr P, Edwards S, Attard G, **de Bono J**, Young BD, Foster CS, Reuter V, Moller H, Oliver TD, Berney DM, Scardino P, Cuzick J, Cooper CS, Lu YJ. The identification of chromosomal translocation, t (4;6)(q22;q15), in prostate cancer. *Prostate Cancer Prostatic Dis*. 2010 Feb 23.
125. Reid AH, Attard G, Ambrosine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Møller H, Reuter VE, Scardino PT, Cuzick J, **de Bono JS**, Cooper CS. Transatlantic Prostate Group. Molecular characterization of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. *Br J Cancer*. 2010 Feb 16;102(4):678-84. Epub 2010 Jan 26.
126. Foster CS, Dodson AR, Ambrosine L, Fisher G, Møller H, Clark J, Attard G, **de-Bono J**, Scardino P, Reuter VE, Cooper CS, Berney DM, Cuzick J. Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. *Br J Cancer*. 2009 Oct 6;101(7):1137-44. Epub 2009 Aug 25.
-



127. Reid AH, Protheroe A, Attard G, Hayward N, Vidal L, Spicer J, Shaw HM, Bone EA, Carter J, Hooftman L, Harris A, **de Bono JS**. A first-in-man phase I and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 amino peptidases, in patients with advanced solid tumors. *Clin Cancer Res*. 2009 Aug 1;15(15):4978-85. Epub 2009 Jul 28.
128. Attard G, Rizzo S, Ledaki I, Clark J, Reid AH, Thompson A, Khoo V, **de Bono JS**, Cooper CS, Hudson DL. A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies. *Prostate*. 2009 Oct 1;69(14):1507-20.
129. Lin CC, Beeram M, Rowinsky EK, Takimoto CH, Ng CM, Geyer CE Jr, Denis LJ, **de Bono JS**, Hao D, Tolcher AW, Rha SY, Jolivet J, Patnaik A. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. *Cancer Chemother Pharmacol*. 2009 Dec;65(1):167-75. Epub 2009 May 16.
130. Attard G, Jameson C, Moreira J, Flohr P, Parker C, Dearnaley D, Cooper CS, **de Bono JS**. Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity. *J Clin Pathol*. 2009 Apr;62(4):373-6. Epub 2008 Dec 9.
131. Jhavar S, Brewer D, Edwards S, Kote-Jarai Z, Attard G, Clark J, Flohr P, Christmas T, Thompson A, Parker M, Shepherd C, Stenman UH, Marchbank T, Playford RJ, Woodhouse C, Ogden C, Fisher C, Kovacs G, Corbishley C, Jameson C, Norman A, **de Bono J**, Bjartell A, Eeles R, Cooper CS. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. *BJU Int*. 2009 May;103(9):1256-69. Epub 2008 Nov 25.
132. Yap TA, **de Bono JS**. Targeting the HGF/c-Met Axis: State of Play. *Mol Cancer Ther*. 2010 May 9(5) 1077-9
133. Attard G, Reid AH, Dearnaley D, **de Bono JS**. New prostate cancer drug: Prostate cancer's day in the sun. *BMJ*. 2008 Aug 11;337:a1249. doi: 10.1136/bmj.a1249.
134. Arkenau HT, Olmos D, Ang JE, Barriuso J, Karavasilis V, Ashley S, **de Bono J**, Judson I, Kaye S. 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? *Eur J Cancer*. 2008 Jul;44(11):1536-40. Epub 2008 Jun 10.
135. Arkenau HT, Barriuso J, Olmos D, Ang JE, **de Bono J**, Judson I, Kaye S. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. *J Clin Oncol*. 2009 Jun 1;27(16):2692-6. Epub 2009 Mar 30. PubMed PMID: 19332724.
136. Reid HMR, Attard G, Danila D, Oommen, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LWMM, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI **de Bono JS**. Significant and sustained antitumour activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. *J Clinical Oncology* 2010, Mar 20;28(9):1489-95. Epub 2010 Feb 16.
137. Carden CP, Sarker D, Postel-Vinay S, Yap TA, Attard G, Banerji U, Garrett MD, Thomas GV, Workman P, Kaye SB, **de Bono JS**. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? *Drug Discov Today*. 2010 Feb;15(3-4):88-97. Epub 2009 Dec 2.
138. Danila DC, Morris MJ, **de Bono JS**, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bublely GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuizska M, Larson SM, Schwartz LH, Fleisher M, Scher HI. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. *J Clin Oncol*. 2010 Mar 20;28(9):1496-501. Epub 2010 Feb 16
139. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, **de Bono JS**, Kaye SB. Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval. *J Clin Oncol*. 201 May 20;28 2512-9.
140. Lassen U, Molife LR, Sorensen M, Engelholm SA, Vidal L, Sinha R, Penson RT, Buhl-Jensen P, Crowley E, Tjornelund J, Knoblauch P, **de Bono JS**. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. *Br J Cancer*. 2010 Jun 29;103(1):12-7. Epub 2010 Jun 15.
141. Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Newbold KN, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, **de Bono JS**, Melcher AA. Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers. *Clin Cancer Res* June 1, 2010 15:3067:3067-2077; [Epub 1 May 2010].
142. Yap TA, Sandhu, SK, Workman P, **de Bono JS**. Envisioning the future of early anticancer drug development. *Nature Reviews Cancer* 2010 Jul 10 (7) 514-23.
143. Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, **de Bono JS**. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. *Br J Cancer*. 2010 Jul 27;103(3):332-9. Epub 2010 Jul 13.
-

144. Brunetto AT, Kristeleit RS, **de Bono JS**. Early oncology clinical trial design in the era of molecular-targeted agents. *Future Oncol*. 2010 Aug;6(8):1339-52.
145. Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Buhl-Jensen P, Molife R, Brown R, **de Bono JS**, Evans TR. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). *Cancer Chemother Pharmacol*. 2010 Aug 13. [Epub ahead of print]
146. Yap TA, **de Bono JS**, Kaye SB, Tutt A, Ashworth A, Schellens JH. Reply to J. Veeck et al. *J Clin Oncol*. 2010 Aug 2. [Epub ahead of print] No abstract available
147. Brunetto AT, Sarker D, Papadatos-Pastos D, Fehrmann R, Kaye SB, Johnston S, Allen M, **de Bono JS**, Swanton C A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. *Br J Cancer*. 2010 Aug 24;103(5):607-12. Epub 2010 Jul 27
148. **de Bono JS** and Ashworth A. Translating cancer research into targeted therapeutics. *Nature* 2010. Vol 467 543:549
149. Olmos D, Basu B, **de Bono JS**. Targeting IGF Signaling: Rational Combination Strategies. *Mol Cancer Ther* 2010 Sep 9 (9) 2447-9
150. Hammond-Thelin LA, Thomas MB, Iwasaki M, Abbruzzese JL, Lassere Y, Meyers CA, Hoff P, **de Bono J**, Norris J, Matsushita H, Mita A, Rowinsky EK. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies. *Invest New Drugs*. 2010 Sep 14. [Epub ahead of print] PubMed PMID: 20839029.
151. **de Bono JS**, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet*. 2010 Oct 2;376(9747):1147-54.
152. Brunetto AT, Ang JE, Olmos D, Tan D, Barriuso J, Arkenau HT, Yap TA, Molife LR, Banerji U, **de Bono J**, Judson I, Kaye S. A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition. *Eur J Cancer*. 2010 Oct;46(15):2739-45. Epub 2010 Aug 11. PubMed PMID: 20667711.
153. Attard G, Reid AH, **de Bono JS**. Abiraterone acetate is well tolerated without concomitant use of corticosteroids. *J Clin Oncol*. 2010 Oct 10;28(29):e560-1; author reply e562. Epub 2010 Aug 30. No abstract available
154. Coumans FA, Doggen CJ, Attard G, **de Bono JS**, Terstappen LW. All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. *Ann Oncol*. 2010 Sep;21(9):1851-7
155. Bianchini D, Zivi A, Sandhu S, **de Bono JS**. Horizon scanning for novel therapeutics for the treatment of prostate cancer. *Ann Oncol*. 2010 Oct;21 Suppl 7:vii43-vii55.
156. Jones RL, Olmos D, Thway K, Fisher C, Tunariu N, Postel-Vinay S, Scurr M, **de Bono J**, Kaye SB, Judson IR. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. *Cancer Chemother Pharmacol*. 2010 Nov 11. [Epub ahead of print] PubMed PMID: 21069341.
157. Zivi A, Massard C, **De-Bono J**. Changing therapeutic paradigms in castrate-resistant prostate cancer. *Clin Genitourin Cancer*. 2010 Dec 1;8(1):17-22. PubMed PMID: 21208851.
158. Talbot DC, Ranson M, Davies J, Lahn M, Callies S, André V, Kadam S, Burgess M, Slapak C, Olsen AL, McHugh PJ, **de Bono JS**, Matthews J, Saleem A, Price P. Tumor survivin is down regulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. *Clin Cancer Res*. 2010 Dec 15; 16(24):6150-8. Epub 2010 Nov 1. PubMed PMID: 21041181.
159. Basu B, Olmos D, **de Bono JS**. Targeting IGF-1R: throwing out the baby with the bathwater? *Br J Cancer*. 2011 Jan 4; 104(1):1-3. PubMed PMID: 21206496; PubMed Central PMCID: PMC3039814.
160. Trump DL, Payne H, Miller K, **de Bono JS**, Stephenson J 3rd, Burris HA 3rd, Nathan F, Taboada M, Morris T, Hubner A. Preliminary study of the specific endothelin A receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. *Prostate*. 2011 Jan 26. doi: 10.1002/pros.21342. [Epub ahead of print] PubMed PMID: 21271613.
161. Yap TA, Sandhu SK, Carden CP, **de Bono JS**. Poly (ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. *CA Cancer J Clin*. 2011 Jan-Feb;61(1):31-49. Epub 2011 Jan 4. PubMed PMID: 21205831.
162. Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V, Twigger K, Coffey M, Mettinger K, Gill G, Evans TR, **de Bono JS**. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. *Clin Cancer Res*. 2011 Feb 1;17(3):581-8. Epub 2010 Nov 24. PubMed PMID: 21106728.
163. Attard G, **de Bono JS**. Utilizing Circulating Tumor Cells: Challenges and Pitfalls. *Current Opinion in Genetics & Development* 2010, 21:1-9.
-

164. Attard G, Richards J, **de Bono JS**. Pathway. *Clin Cancer Res*. 2011 Apr 1;17(7):1649-57. Epub 2011 Mar 3 [Epub ahead of print] PubMed PMID: 21372223.
165. Pacey S, Wilson RH, Walton MI, Eatock M, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, **de Bono JS**, Raynaud FI, Workman P, Judson IR. A Phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced, solid tumors. *Clin Cancer Res*. 2011 Feb 3. [Epub ahead of print] PubMed PMID: 21278242
166. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, Collins D, Desouza NM, Leach MO, Savage RE, Waghorne C, Chai F, Garmey E, Schwartz B, Kaye SB, **de Bono JS**. Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies. *J Clin Oncol*. 2011 Mar 7. [Epub ahead of print] PubMed PMID: 21383285.
167. Kraan J, Sleijfer S, Strijbos MH, Ignatiadis M, Peeters D, Pierga JY, Farace F, Riethdorf S, Fehm T, Zorzino L, Tibbe AG, Maestro M, Gisbert-Criado R, Denton G, **de Bono JS**, Dive C, Foekens JA, Gratama JW. External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: A feasibility study. *Cytometry B Clin Cytom*. 2011 Mar;80(2):112-8. doi: 10.1002/cyto.b.20573. Epub 2010 Nov 10. PubMed PMID: 21337491.
168. **de Bono JS**, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Salhen Mansoor Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI for the COU-AA-301 investigators. Abiraterone and Increased Survival in Metastatic Prostate Cancer. *N Engl J Med*. 2011 May 26;364(21):1995-2005 PMID 21612468
169. Olmos D, Barker D, Sharma R, Brunetto AT, Yap T, Taegtmeier AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, **de Bono JS**, Blagden SP. Phase I study of GSK461364, a specific and competitive Polo-like Kinase 1 (PLK1) inhibitor in patients with advanced solid malignancies. *Clin Cancer Res*. 2011 May 15;17(10):3420-30. Epub 2011 Apr 1.
170. Olmos D, Baird RD, . Yap TA, Massard C , Pope L, Sandhu SK, Dukes J, Papadatos-Pastos D, Grainger P, Kaye SB, **de Bono JS**. Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials. *Clin Cancer Res*. 2011 Apr 29. [Epub ahead of print].
171. Attard G, Crespo M, Lim AC, Pope L, Zivi A, **de Bono JS**. Reporting the Capture Efficiency of a Filter-Based Microdevice: A CTC Is Not a CTC Unless It Is CD45 Negative. *Clin Cancer Res*. 2011;17:3048-3049.
172. **de Bono JS**, Sandhu S, Attard G. Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors *Cancer Cell* 2011 19, May 17 ; 573- 574.
173. Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, **De-Bono J**, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV. A HIF-Regulated VHL-PTP1B-Src Signalling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma. *Sci Transl Med*. 2011 Jun 1;3(85):85ra4
174. Beltran H, Beer TM, Carducci MA, **de Bono JS**, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF. New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety. *Eur Urol*. 2011 May 4. [Epub ahead of print
175. Messiou C, Cook G, Reid AH, Attard G, Dearnaley D, **de Bono JS**, de Souza NM The CT flare response of metastatic bone disease in prostate cancer. *Acta Radiol*. 2011 Jun 1;52(5):557-61. Epub 2011 Mar 23. PMID 21498309
176. Postel-Vinay S, Gomez-Roca C, Molife LR, Anghan B, Levy A, Judson I, **De Bono JS**, Soria JC, Kaye S, Paoletti X. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? *J Clin Oncol*. 2011 May 1;29(13):1728-35. Epub 2011 Mar 28.
177. Attard G, **de Bono JS**, Translating Scientific Advancement into Clinical Benefit for Castration-Resistant Prostate Cancer Patients. *Clin Cancer Res*. 2011; 17:3867-3875. PMID 21680542
178. Moreno-Garcia V, Cassier PA, **de Bono JS**. Parallel Anticancer Drug Development and Molecular Stratification to Qualify Predictive Biomarkers: Dealing with Obstacles Hindering Progress; *Cancer Discovery* 2011;1:207-212.
179. **de Bono JS**, Molife LR, Sonpavde G, Maroto JP, Calvo E, Cartwright TH, Loesch DM, Feit K, Das A, Zang EA, Wanders J, Agoulnk S, Petrylak DP. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy . *Ann Oncol*. 2011 Sep 7. [Epub ahead of print]
180. AW Tolcher, D Quinn, A Ferrari, F Ahmann, G Giaccone, T Drake, A Keating, **JS de Bono**. A Phase II study of YM155, a small molecule suppressor of surviving, in castration resistant taxane-pretreated prostate cancer. *Ann Oncol*. 2011 Aug 22. [Epub ahead of print]
181. **de Bono JS**. Interview with Johann de Bono for Future Oncology "... the 'holy grail' is developing drugs that will cause no side effects but will kill tumour cells' *Future Oncology* (2012) 8 (11) 1-2.
-

182. Small EJ, de Bono JS. Prostate Cancer: evolution or revolution? *J Clin Oncol*. 2011 Sept 20;29(27):3595-8 Epub 2011 Aug 22. PMID 21859996
183. Yap TA, Zivi A, Omlin A, **de Bono JS**. The changing therapeutic landscape of castration-resistant prostate cancer. *Nat Rev Clin Oncol* 2011 Aug 9. PMID 21826082
184. Yap TA, Sandhu SK, Alam SM, **de Bono JS**. HGF/c-MET Targeted Therapeutics: Novel Strategies for Cancer Medicine. [Epub ahead of print]
185. Sandhu SK, YAP TA, **de Bono JS**. The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment. [Epub ahead of print].
186. Yap TA Olmos, Molife LR, **de Bono JS**. Targeting the insulin-like growth factor signalling pathway: figitumumab and other novel anticancer strategies. *Expert Opin Investig Drugs*. 2011 Sept; 209): 1293-1304.
187. Messiou C, Collins DJ, Giles S, **de Bono JS**, Bianchini D, de Souza NM. Assessing response in bone metastases in prostate cancer with diffusion weighted MRI. *Eur Radiol*. 2011 Oct.; 21 (10): 2169-2177. Epub 2011 June 28. PMID 21710270
188. Eichholz A, Ferraldeschi R, Attard G, **de Bono JS**. Putting the Brakes on Continued Androgen Receptor Signalling in Castration-Resistant Prostate Cancer. *Mol Cell Endocrinol*. 2012 Sept 1. PMID 21986558
189. Sartor O, Michels RM, Massard C, **de Bono JS**. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. *Oncologist*. 2011;16(11):1487-97. Epub 2011 Nov 2 PMID 22048000
190. Attard G, Reid AHM, Auchus R, Hughes BA, Cassidy AM, Oommen NB, Thompson E, Folkard E, Dowsett M, Arlt W, **de Bono JS**. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. *J Clin Endocrinol Metab*. 97 (2): 507-16 2012 Feb PMID 22170708
191. Lighthart ST, Coumans FA, Attard G, Cassidy AM, **de Bono JS**, Terstappen LW. Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. *PLoS One*. 2011;6(11):e27419 Epub 2011 Nov 7.
192. **de Bono JS**, Yap TA. Future directions in the evaluation of c-MET-driven malignancies. *Ther Adv Med Oncol*. 2011 Nov;3(1 Suppl):S51-60.
193. **de Bono JS**, Yap TA. c-MET: an exciting new target for anticancer therapy. *Ther Adv Med Oncol*. 2011 Nov;3(1 Suppl):S3-5
194. Massard C, Sandhu SK, Blanco M, Papadatos-Pastos D, Carden C, **de Bono JS**, Saran F, Molife LR, Kaye SB, Soria JC and Banerji. Towards a Better Dialogue between Neuro-oncologists and Phase I Investigators letter to JCO 2011
195. Molife LR, **de Bono JS**. Belinostat: clinical applications in solid tumors and lymphoma. *Expert Opinion* 2011. Posted online on November 3, 2011. (doi:10.1517/13543784.2011.629604)
196. Pezaro CJ, Mukherji D, **de Bono JS**. Abiraterone acetate: redefining hormone treatment for advanced prostate cancer. *Drug Discov. Today* 17(5-6) 221-226 2012 Mar. PMID 22198164
197. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, **de Bono JS**, Tolcher AW. First in Man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumours. *J Clin Oncol*. 2011 Dec 10;29(35):4688-95. Epub 2011 Oct 24
198. Mukherji D, Pezaro CJ, **de Bono JS**. MDV3100 for the treatment of prostate cancer. *Expert Opin Investig Drugs*. 2012 Jan 10. PMID 22229405
199. Fizazi K, **de Bono JS**, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. *Eur J Cancer*. 2012 Jan;48(1):85-93. Epub 2011 Nov 28
200. Mezynski J, **de Bono JS**. Hormone Treatment for Prostate Cancer . *Future Medicine* 2011. DOI:10 2217/EBO 11.107. In Press
201. Carden C, Stewart A, Thavasu P. Kipps, E, Pope L, Crespo M, Miranda S, Attard G, Garrett M, Clarke P. Workman P, **de Bono JS**, Gore M, Kaye S, Banerji U. The association of PI3 kinase signaling and chemo-resistance in advanced ovarian cancer. *Mol Cancer Ther*. July 2012.
202. Banerji U, van Doorn L, Papadatos-Pastos D, Kristeleit R, Debnam P, Tall, M, Stewart A, Raynaud F, Garrett MD, Toal M, Hooftman, **de Bono JS**, Verweij J, Eskens F ALM. A Phase I pharmacokinetic and pharmacodynamics study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. 2012 *Clin Can Res*. May 1 2687-2694
203. Richards J, Lim A, Hay C, Taylor A, Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W, McEwan I, **de Bono JS**, Attard G. Interactions of abiraterone, eplerenone and prednisolone with wild-type and mutant androgen receptor: a
-

- rationale for increasing abiraterone exposure or combining with MDV3100. *Cancer Res.* 2012 May 1;72(9):2176-82. Epub 2012 Mar 12.
204. Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, Hunt J, Sheridan E, Baikady B, Sarvadikar A, Maier G, Reid AHM, Cassidy AM, Olmos D, Attard G, **de Bono JS**. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance. *Ann Oncol.* 23(11) 2943-7 2012 Jul 5. PMID 22771826
205. Reid AHM, Attard G, Brewer D, Miranda S, Riisnaes, Clark J, Hylands L, Merson S, Vergis R, Jameson C, Høyer S, Sørensen KD, Borre M, Jones C, **de Bono JS**, Cooper C. Novel, gross chromosomal alterations involving *PTEN* cooperate with allelic loss in prostate cancer. *Mod Pathol* 25(8) 902-10 Aug 2012. PMID 22460813
206. Mukherji D, **de Bono JS**, et al. Management of Metastatic Prostate Cancer : Recent Advances. *Drugs.* 72(8):1011-28, 2012 May 28. PMID 22621691
207. Daniele G, Corral J, Molife LR, de Bono JS. FGF Receptor Inhibitors: Role in Cancer Therapy. *Curr Oncol Rep* 05 Feb 2012
208. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, **de Bono JS**; the AFFIRM Investigators Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. *N Engl J Med.* 367(13) 1187-97, 27 Sep 2012. PMID 22894553
209. Pienta KJ, Machiels JP, Schrijvers D, Alekseev B, Shkolnik M, Crabb SJ, Li S, Seetharam S, Puchalski TA, Takimoto C, Elsayed Y, Dawkins F, **de Bono JS**. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. *Invest New Drugs.* Jun 2013.
210. Basu B, Vitfell-Pedersen J, Moreno Garcia V, Puglisi M, Tjokrow A, Shah K, Malvankar S, Angham B, **de Bono JS**, Kaye SB. Creatinine Clearance is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials. *Oncology* 83 (4) 177-182 Aug 2012
211. Basu B, Sandhu SK, **de Bono JS**. Parp Inhibitors. Mechanism of Action and their Potential Role in the Prevention and Treatment of Cancer. *Drugs* 2012 72 (12):1-2.
212. Messiou C, Orton M, Ang JE, Collins DJ, Morgan VA, Mears D, Castellano I, Padadatos-Pastos D, Brunetto A, Tunariu **de Bono JS** et al. Advanced Solid Tumors Treated with Cediranib: Comparison of dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity. *Radiology* 13 August 2012
213. Sandhu SK, Moreno V, Wilding G, Omlin, Schelman WR, Miranda S, Riisnaes R, Hylands L, Attard G, Cassidy A, **de Bono JS** et al. Phase I study of a Poly (ADP)-Ribose Polymerase (PARP) Inhibitor MK 4827 (MK) with Antitumour Activity in Sporadic Castration Resistant Prostate Cancer (CRPC). *Asia-Pacific Journal of Clinical Oncology* 8 33-33 July 2012
214. Ferraldeschi R, Pezaro C, Karavasilis V, **de Bono JS**. Abiraterone and Novel Antiandrogens: Overcoming Castrations Resistance in Prostate Cancer. *Annu Rev Med.* 64(1-13), 2012 Sep 27. PMID 23020876
215. V Moreno Garcia, P Thavas, M Blanco Codesido, L R Molife, J Vitfell Pedersen, M Puglisi, B Basu, K Shah, J Iqbal, **J S de Bono**, S B Kaye and U Banerji. Association of creatine kinase and skin toxicity in phase I trials of anticancer agents. *British Journal of Cancer* (2012) 107, 1797–1800. doi:10.1038/bjc.2012.482 Published online 25 October 2012
216. Olmos D, Brewer D, Clark J, Danila DD, Parker C, Attard G, Fleischer M, Reid A, Castro E, Sandhu SK, Barwell L, Oomen NB, Carreira S, Drake CG, Jones R, Cooper CS, Scher HI, **de Bono JS**. Blood mRNA expression signatures can stratify castration resistant prostate cancer patients and predict poor outcome. 2012. *Lancet Oncol.* 2012 Nov;13(11):1114-24. doi: 10.1016/S1470-2045(12)70372-8. Epub 2012 Oct 9. PMID 23059046
217. Logothetis CJ, Scher HI, **de Bono JS**, Basch EM, Molina A, Haqq CM, Kheoh TS, Hao Y et.al .Effect of Abiraterone Acetate on Pain Control and Skeletal-Related Events in Patients With Metastatic Castration-Resistant Prostate Cancer Post Docetaxel: Results of the COU-AA-301 Study. *Lancet Oncol.* 2012 Dec;13(12):1210-7. Epub 2012 Nov 9. PMID: 23142059
218. Sandhu SK, Wilding G, Schelman WR, Omlin A, Kriescher N, Carpenter C, Iannone R, Kay SB, **de Bono JS**. Wenham RM. Final Results of First in Man Trial of MK4827, a poly (ADP-ribose) Polymerase (PARP) inhibitor with Antitumour Activity in BRCA Carriers and Sporadic Cancer Patients. *European Journal of Cancer* . 48. 107-108 Nov 2012.
219. **de Bono JS**. The Challenges of Drug Combination Studies. *European Journal of Cancer* 48. 9-9 Nov 2012
220. Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Felho JS, Moreno V, **de Bono JS**, et.al. Secondary Mutations in BRCA2 Associated with Clinical Resistance to a PARP inhibitor. *J Pathol* 20 Nov 2012.
221. Sternberg CN, Molina A, North S, Mainwaring P, Fizazi K, Hao Y, Rothman M., Gagnon DD, Kheoh T, Haqq CM, Cleeland, C, **de Bono J.S.**, Scher HI. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. *Ann Oncol* 24(4) 1017-1025, 2012 Sep 24. PMID 23152362
-

222. Ryan CJ, Smith MR, **de Bono JS**, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PFA, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttman H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin M-E, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf for the COU-AA-302 Investigators. Abiraterone in Metastatic Prostate Cancer with Previous Chemotherapy. *New Engl. J. Med.* 368(2) 138-18 December 14 2012. PMID 23228172
223. Scher HI, **de Bono JS**. Investigators AFFIRM. Enzalutamide in Prostate Cancer after Chemotherapy REPLY. *New England Journal of Medicine* 367(25) 2448-2449 20 Dec 2012. PMID 23252532
224. Yap T A, Pezaro CJ, **de Bono JS**. Cabazitaxel in metastatic castration-resistant prostate cancer. *Expert Rev. Anticancer Ther.* 12(9), 00-00 (2012)
225. Ferraldeschi R, **de Bono JS**. Agents that target androgen synthethis in castration-resistant prostate cancer. *Cancer J* 19(1): 34-42 Jan 2013.
226. Mukherji D, Pezaro CJ, Shamseddine A, **de Bono JS**. New treatment developments applied to elderly patients with advanced prostate cancer . *Cancer Treat Rev*, 02 Jan 2013.
227. Ferraldeschi R, Attard G, **de Bono JS**. Novel Strategies to test biological hypotheses is early drug development for advanced prostate cancer. *Clin Chem.* 59 (1):75-84 Jan 2013. PMID 23204221
228. Omlin A, Pezaro C, Mukherji D, Mulick-Cassidy A, Sandhu S, Bianchini D, Olmos D, Ferraldeschi R, Maier G, Thompson E, **de Bono JS** et.al. Improved Survival in a Cohort of Trial participants with Metastatic Castration-Resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. *Eur Urol* 64(2) 300-6, 04 Jan 2013. PMID 23313031
229. Sandhu SK, Papadopoulos K, Fong P PC, Patnaik A, Messiou C, Olmos D, Wang GTT, Tromp BJ, Puchalski TA, Balkwill E, **de Bono JS**. A first-in-human , first-in-class phase I study of carlumab (CNTO888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumours. *Cancer Chemother Pharmacol.* 6 Feb 2013.
230. Parker CC, Sydes MR, Mason MD, Clarke NW, Aebersold D, **de Bono JS**, Dearnaley DP, Ritchie AWS, Russell, JM, Thalmann G, Parmar MKB, James ND. Prostate Radiotherapy for Men with Metastatic Disease: A New comparison in the STAMPEDE Trial. *Clinical Oncology* (2013) 13 March .
231. Reardon DA, Groves MD, Wen PY, Nabors LB, Mikkelsen T, Rosenfeld S, Raizer J, Barriuso J, McLendon RE, Suttle AB, **de Bono JS** et.al. A Phase I/II Trial of Pazopanib in combination with Lapatinib in Adult patients with Relapsed Malignant Glioma. *Clin Cancer Res.* 30 January 2013.
232. Bahl A, Oudard S, Tombal B, Ozgüroglu M, Hansen S, Kocak I, Gravis G, Devin J, Shen L, **de Bono JS**, et al. Impact of Cabazitaxel on 2 year survival and palliation of tumour- related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. *Annals of Oncology* 30 May 2013
233. Parker CC, Sydes MR, Mason MD, Clarke NW, Aebersold D, **de Bono JS**, Dearnaley DP, Ritchie AW, Russell JM, Thalmann G, et al. Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer; Evaluation of Drug Efficacy (STAMPEDE) trial. *BJU Int* 111 (5) 697-699 May 2013.
234. Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM, Grant RP, **de Bono JS**, Scher HI. Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial. *J Clin Oncol.* 31(22) 2791-8 1 Aug 2013. PMID 23816964
235. Pezaro C, Mukherji D, Tunariu N, Cassidy AM, Omlin A, Bianchini D, Seed G, Reid AH, Olmos D, **de Bono JS**, Attard G. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. *Br J Cancer* 109(2):325-331 23 July 2013. PMID 23807167
236. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, **de Bono JS**, Wenham RM. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. *Lancet Oncol.* 14(9)882-892 Aug 2013.
237. Takimoto C, Seetharam S, McIntosh T, **de Bono JS**, Sandhu SK, Tolcher A, David HM et al. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2 total CCL2 and carlumab (CNTO888): concentration time data. *J Clin Pharmacol* 23 July 2013.
238. Omlin A, J Pezaro C, Zaidi S, Lorente D, Mukherji D, Bianchini D, Ferraldeschi R, Sandhu S, Dearnaley D, Parker C, **de Bono JS**, et al.. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.. *Br J Cancer* 109(5) 1079-84, 08 Aug 2013. PMID 23928659
239. Meulenbeld HJ, **de Bono JS**, Tagawa ST, Whang YE, Li X, Heath KH, Zandvliet AS, Ebbinghaus SW, Hudes GR, de Wit R. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).. *Cancer Chemother Pharmacol* 07 Aug 2013.
-

240. Ang JE, Gourley C, Powell B, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, **de Bono JS**, et al. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of poly(ADP-ribose) polymerase inhibitor resistance: a multi-institutional study.. *Clin Cancer Res* 06 Aug 2013
241. Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A, Fourneau N, Hellemans P, Elsayed Y, Mcclue S, Smit JW, Forslund A, Phelps C, Camm J, Evans TRJ, **de Bono JS**, Banerji U. A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors. *Clinical Cancer Research* **19**(15):4262-4272 01 Aug 2013.
242. Bahl A, Masson S, Birtle A, Chowdhury S, **de Bono JS**. Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents. *Cancer Treat Rev* 16 August 2013. PMID 23958310
243. Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, **de Bono JS**, Scher HI, COU-AA-301 Investigators. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. *Eur J Cancer* S0959-8049(13) 22 August 2013. PMID 23973186
244. Molife LR, Rudman SM, Alam S, Tan DS, Kristeleit H, Middleton G, Propper D, Bent L, Stopfer P, Uttenreuther-Fischer M, Wallenstein G, **de Bono J** et al.. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.. *Cancer Chemother Pharmacol* **72**(6):1213-1222 Oct 2013.
245. Goodman OB, Flaig TW, Molina A, Mulders PF, Fizazi K, Suttman H, Li J, Kheoh T, **de Bono JS**, Scher HI. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.. *Prostate Cancer Prostatic Dis* 01 Oct 2013. PMID 24080993
246. Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, **de Bono JS**. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.. *Eur J Cancer* S0959-8049(13) 25 Sep 2013. PMID 24074764
247. Brunetto AT, Ang JE, Lal R, Olmos D, Molife LR, Kristeleit R, Parker A, Casamayor I, Olaleye M, Mais A, Hauns B, Strobel V, Hentsch B, **de Bono JS** et al.. First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors.. *Clin Cancer Res* 24 Sep 2013.
248. Halabi S, Armstrong AJ, Sartor O, **de Bono J**, Kaplan E, Lin CY, Solomon NC, Small EJ. Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy. *J Clin Oncol* 31(31) 3944-50, 07 Oct 2013. PMID 24101043
249. Mateo J, Ong M, Tan DS, Gonzalez MA, **de Bono JS**. Appraising iniparib, the PARP inhibitor that never was-what must we learn?. *Nat Rev Clin Oncol* 15 Oct 2013
250. Bianchini D, Omlin A, Pezaro C, Lorente D, Ferraldeschi R, Mukherji D, Crespo M, Figueiredo I, Miranda S, Riisnaes R, Zivi A, Buchbinder A, Rathkopf DE, Attard G, Scher HI, **de Bono J**, Danila DC. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. *Br J Cancer* 29 Oct 2013.
251. Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, **de Bono J**, et al. Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy. *J Natl Cancer Inst* 17 Oct 2013. PMID 24136890
252. Pezaro C, Omlin A, Lorente D, **de Bono J**. Management of patients with castration-resistant disease. *Hematol Oncol Clin North Am* **27**(6):1243-1260 Dec 2013
253. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efsthathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, **de Bono JS**, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. *Lancet Oncol* 07 Nov 2013
254. Omlin A, Pezaro CJ, Zaidi S, Lorente D, Mukherji D, Bianchini D, Ferraldeschi R, Sandhu S, Dearnaley D, Parker C, **de Bono JS**, et al.. Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'. *Br J Cancer* 03 Dec 2013
255. Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, **de Bono JS**, Attard G. 'Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents' *Eur Urol* 17 Dec 2013
-



256. Mateo J, Smith A, Ong M, **de Bono JS**. 'Novel drugs targeting the androgen receptor pathway in prostate cancer' *Cancer Metastasis Rev* 04 Jan 2014 (Journal article)
257. Lorente D, **De Bono JS**. 'Molecular alterations and emerging targets in castration resistant prostate cancer' *Eur J Cancer* 09 Jan 2014 (Journal article)
258. Lorente D, Bianchini D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, **De Bono JS**. Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer.. *Eur J Cancer* 13 Jan 2014
259. Khan K, Ang JE, Starling N, Sclafani F, Shah K, Judson I, Molife LR, Banerji U, **de Bono JS**, Cunningham D, et al.. Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit.. *Gastric Cancer* 21 Jan 2014
260. Mukherji D, Omlin A, Pezaro C, Shamseddine A, **de Bono J**. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.. *Cancer Metastasis Rev* 23 Jan 2014
261. Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D, Vera-Badillo F, Seah JA, Attard G, Knox JJ, Sridhar SS, Tannock IF, **de Bono JS**, Joshua AM Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.. *Ann Oncol* 23 Jan 2014
262. Padhani AR, Makris A, Gall P, Collins DJ, Tunariu N, **de Bono JS**. Therapy monitoring of skeletal metastases with whole-body diffusion MRI.. *J Magn Reson Imaging* 10 Feb 2014
263. Sternberg CN, **de Bono JS**, Chi KN, Fizazi K, Mulders P, Cerbone L, Hirmand M, Forer D, Scher HI. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.. *Ann Oncol* **25**(2):429-434 Feb 2014
264. Molife LR, Omlin A, Jones RJ, Karavasilis V, Bloomfield D, Lumsden G, Fong PC, Olmos D, O'Sullivan JM, Pedley I, et al.. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.. *Future Oncol* **10**(2):219-231 Feb 2014
265. Basch EM, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, et al.. Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort.. *Eur Urol* 20 Feb 2014
266. Rathkopf DE, Smith MR, **de Bono JS**, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, et al.. Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302).. *Eur Urol* 06 Mar 2014
267. Ravi P, Mateo J, Lorente D, Zafeiriou Z, Altavilla A, Ferraldeschi R, Sideris S, Grist E, Smith A, Wong S, et al.. External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone.. *Eur Urol* 26 Mar 2014
268. Graham TJ, Box G, Tunariu N, Crespo M, Spinks TJ, Miranda S, Attard G, **de Bono J**, Eccles SA, Davies FE, et al.. Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.. *J Natl Cancer Inst* **106**(4):dju033 01 Apr 2014
269. **de Bono JS**, Piulats JM, Pandha HS, Petrylak DP, Saad F, Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, et al.. Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer.. *Clin Cancer Res* **20**(7):1925-1934 01 Apr 2014
270. Lortot Y, Fizazi K, Jones RJ, Van den Brande J, Molife RL, Omlin A, James ND, Baskin-Bey E, Heeringa M, Baron B, Holtkamp GM, Ouatas T, **De Bono JS**. Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.. *Invest New Drugs* 27 Apr 2014
271. Padhani AR, Makris A, Gall P, Collins DJ, Tunariu N, **de Bono JS**. Therapy monitoring of skeletal metastases with whole-body diffusion MRI. *JOURNAL OF MAGNETIC RESONANCE IMAGING* **39**(5):1049-1078 May 2014
272. Yap TA, Lorente D, Omlin A, Olmos D, **de Bono JS**. Circulating tumor cells: a multifunctional biomarker.. *CLINICAL CANCER RESEARCH* **20**(10):2553-2568 15 May 2014 (Journal article)
-



273. Ferraldeschi R, Welti J, Luo J, Attard G, **de Bono JS**. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.. *Oncogene* 19 May 2014 (Journal article)
274. Attard G, Sydes MR, Mason MD, Clarke NW, Aebbersold D, **de Bono JS**, Dearnaley DP, Parker CC, Ritchie AW, Russell JM, et al.. Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial.. *Eur Urol* 27 Jun 2014 (Journal article)
275. Rodriguez-Vida A, Bianchini D, Van Hemelrijck M, Hughes S, Malik Z, Powles T, Bahl A, Rudman S, Payne H, **de Bono J**, et al.. Is there an anti-androgen withdrawal syndrome with enzalutamide?. *BJU Int* 06 Jun 2014 (Journal article)
276. Wong YNS, Ferraldeschi R, Attard G, **de Bono J**. Evolution of androgen receptor targeted therapy for advanced prostate cancer.. *NATURE REVIEWS CLINICAL ONCOLOGY* **11**(6):365-376 Jun 2014 (Journal article)
277. Ravi P, Mateo J, Lorente D, Zafeiriou Z, Altavilla A, Ferraldeschi R, Sideris S, Grist E, Smith A, Wong S, Bianchini, D; Attard, G; **de Bono, JS** . External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone.. *EUROPEAN UROLOGY* **66**(1):8-11 Jul 2014 (Journal article)
278. Rodrigues DN, Hazell S, Miranda S, Crespo M, Fisher C, **de Bono JS**, Attard G. Sarcomatoid carcinoma of the prostate: ERG fluorescence in situ hybridization confirms epithelial origin.. *Histopathology* 12 Jul 2014 (Journal article)
279. Montgomery B, Kheoh T, Molina A, Li J, Bellmunt J, Tran N, Loriot Y, Efstathiou E, Ryan CJ, Scher HI, **de Bono JS**.. Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301.. *Eur Urol* 10 Jul 2014 (Journal article)
280. Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo FE, Attard G, **de Bono JS**, Tannock IF, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio.. *Cancer* 03 Jul 2014 (Journal article)
281. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis, ID; **de Bono, JS**; Evans, CP; Fizazi, K; Joshua, AM; Tombal, B et al.. Enzalutamide in metastatic prostate cancer before chemotherapy.. *NEW ENGLAND JOURNAL OF MEDICINE* **371**(5):424-433 31 Jul 2014 (Journal article)
282. Mateo J, Gerlinger M, Rodrigues D, **de Bono JS**. The promise of circulating tumor cell analysis in cancer management. *Genome Biol* **15**(8):448 30 Aug 2014 (Journal article)
283. Saad F, **de Bono J**, Shore N, Fizazi K, Loriot Y, Hirmand M, Franks B, Haas GP, Scher HI. Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial.. *Eur Urol* 26 Aug 2014 (Journal article)
284. Merseburger AS, Scher HI, Bellmunt J, Miller K, Mulders PF, Stenzl A, Sternberg CN, Fizazi K, Hirmand M, Franks B, Haas GP, **de Bono J**, de Wit R... Enzalutamide in European and North American men participating in the AFFIRM trial.. *BJU Int* 14 Aug 2014 (Journal article)
285. Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, **de Bono J**. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.. *Eur Urol* 06 Aug 2014 (Journal article)
286. Ong M, Carreira S, Goodall J, Mateo J, Figueiredo I, Rodrigues DN, Perkins G, Seed G, Yap TA, Attard G, **de Bono JS** .. Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.. *Br J Cancer* **111**(5):828-836 26 Aug 2014 (Journal article)
287. Puglisi M, Thavasu P, Stewart A, **de Bono JS**, O'Brien MER, Popat S, Bhosle J, Banerji U. AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.. *LUNG CANCER* **85**(2):141-146 Aug 2014 (Journal article)
288. Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, Forer D, Hirmand M, **de Bono JS**. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.. *Lancet Oncol* **15**(10):1147-1156 Sep 2014 (Journal article)
289. Mateo J, Berlin J, **de Bono JS**, Cohen RB, Keedy V, Mugundu G, Zhang L, Abbattista A, Davis C, Gallo Stampino C, et al.. A first-in-human study of the anti- $\alpha 5\beta 1$  integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors.. *Cancer Chemother Pharmacol* 12 Sep 2014 (Journal article)
-

290. Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos K, Olmos D, Baird RD, Delgado LM, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, Heaton SP, Swales K, deSouza NM, Leach MO, Garrett MD, Sullivan DM, **de Bono JS**, Tolcher A.. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.. *Clin Cancer Res* 19 Sep 2014 (Journal article)

### **Submitted Manuscripts: Book Chapters**

**JS de Bono**, AW Tolcher, EK. Rowinsky. Tubulin-Targeting Drugs. In *Current Cancer Therapeutics* 4<sup>th</sup> Edition. Churchill Livingstone.

Ten Holte P, Van Emelen K, Janicot M, Fong PC, **de Bono JS**, Arts J. HDAC Inhibition in Cancer Therapy: an increasingly intriguing tale of chemistry, biology and clinical benefit. **Topics in Medicinal Chemistry** January 2007.

**de Bono JS**. Biological agents in cancer therapy. **Medicine; Oncology Issue 36:1 Medicine Publishing, Elsevier Ltd** submitted May 2007

Karavasilis V, Reid A, Sinha R, **de Bono JS**. **Cancer Drug Resistance. Part V: The Reality of Cancer Drugs in the Clinic. Cancer Drug Design and Discovery. Elsevier/Academic Press** November 2007

Workman P, **de Bono JS**. Targeted therapeutics for cancer treatment: Major progress towards personalised molecular medicine. **Submitted 2008 Current Opinion in Pharmacology Vol 8 issue 4. Elsevier Press.**

Yap T, Sarker D, Kaye S B, **de Bono JS**. Functional Imaging: Clinical Applications in Molecular Targeted Therapy. **Imaging in Oncology, 3<sup>rd</sup> Edition Chapter 61. In press October 2009**

### **Research Support:**

1. **American Society of Clinical Oncology** Young Investigator Award awarded by the Breast Cancer Research Foundation.
  2. **Doris-Duke Foundation Clinician-Scientist Award:** for 5 years: \$108,000 annually for 5 years (2002-2006).
  3. **NIH R21 Quick Trials Grant:** \$650,000 over 2 years to perform a phase I and II study of OSI-774, trastuzumab and paclitaxel in patients with HER2 positive metastatic breast carcinoma (Principal Investigator).
  4. **AstraZeneca:** \$250,000 grant to perform an investigator initiated study of Arimidex and Iressa in post-menopausal patients with ER+ metastatic breast carcinoma (Principal Investigator).
  5. **Mesothelioma Applied research Foundation:** \$100,000 to study the importance of polymorphisms of the thymidylate synthase enhancer region (TSER) in the pharmacogenetics of the multitargeted antifolate Alimta (Principal Investigator).
  6. **Pfizer. Dr JS de Bono** . "Molecular evaluation of hormone refractory prostate cancer (HRPC)". Pfizer \$50,000 2005-2007
  7. **Royal Marsden Hospital Research Fund. Dr JS de Bono.**" A molecular study (utilizing array CGH) into the aetiology of hormone refractory prostate cancer". GCRF (RMH) £99,742, 2005-2007
  8. **Prostate Cancer Research Campaign UK Drs JS de Bono, Sian Rizzo, Colin Cooper, Anne Collins, Chris Parker, David Dearnaley, Vincent Khoo, Alan Thompson and David Hudson.** "Isolation, culture and molecular characterization of castration-refractory prostate cancer (CRPC) stem cells from clinical tumour material. £50,000 2004-2006
  9. **Roche. Dr JS de Bono.** "An Open label, Phase II, multicentre study to evaluate the efficacy and safety of a recombinant humanized antibody to HER2 (Pertuzumab) administered every 3 weeks to patients with hormone-refractory prostate cancer who have not been treated with chemotherapy" Roche £71,089.81, 2003-2005
  10. **Immunicon. Dr JS de Bono** "Circulating tumour cells and the prediction of overall survival and progression free survival in patients with androgen independent metastatic prostate carcinoma" Immunicon USA \$US 105,000 (max.)
  11. **Marie Curie. Dr JS de Bono** "Marie Curie Early Stage Training Programme for Molecular Imaging" £19,000 p.a for 3-year project "MRI and PET in Clinical Trials" July 2005
  12. **MRC. Dr JS de Bono, Prof S Kaye, Prof I Judson, Prof M leach, Dr Florence Raynaud, Dr Nandita deSouza, Dr C Parker, Prof C Cooper.** "First Clinical evaluation of a phosphoinositide 3-kinase (PI3K) inhibitor for the treatment of advanced prostate cancer." £576,012.00. 1<sup>st</sup> April 2006 – 31 March 2009 MRC Research Grant.
  13. **Cancer Research UK Drug Development Unit Core Grant;** SB Kaye, **JS de Bono**, I Judson, F Raynaud, P Workman (Starts 2007)
  14. **South of England Prostate Cancer Collaborative;** C Cooper, **JS de Bono**, C Parker, D Dearnaley, CS Foster, A Swain (Starts 2007)
  15. **Experimental Medicine Cancer Centre** grant, SB Kaye, **JS de Bono**, I Judson, P Workman, F Raynaud, M Garrett (Starts 2007) The Prostate Cancer Charity 36 months. Co Applicant with Prof Colin Cooper. "A mechanism-based system of classification for human prostate cancer" £152,474 1st June 2008 **grant number 110722.**
-

16. **CRUK TRICC.** Co Applicant with Prof Colin Cooper. "The NCRI Prostate cancer collaborative Prostate Cancer map project" 2 years 1st June 2008 year 1 £184,644 year 2 £187,739 grant number **C189/A10047**.
  17. **Cancer Research UK/Department of Health** The Institute of Cancer Research and Royal Marsden Hospital Experimental Cancer Medicine Centre (with G Cook, J de Bono, N deSouza, I Judson, M Leach, G Morgan, F Raynaud, P Workman) £500,000 (1<sup>st</sup> yr) **C51/A7401** 01/04/2007-31/03/2012, 60 months.
  18. **Prostate Cancer Research Foundation** JS de Bono, G Attard, J Clark, G Kovacs, M Garrett, M Dowsett, F Raynaud, D Dearnaley, C Parker, C Cooper. Laboratory evaluation of Abiraterone, a novel small molecule inhibitor of androgen synthesis that is safe, and has durable clinical antitumour activity in prostate cancer patients who have failed standard androgen deprivation therapy. 2 years. £142,939
  19. **Cancer Research UK. C12540/A8336** Prof J de Bono, Dr F Raynaud, Dr C Swanton, Prof S Kaye, Prof S Johnson, Prof M Dowsett. A Phase I/II trial of "A Cancer Research UK Phase I/II open label study to evaluate the safety, endocrine effects and anti-tumour activity of abiraterone acetate (CB7630) in patients with oestrogen (ER) or androgen receptor (AR) positive, advanced or metastatic breast carcinoma". £180,000 DDO project from 1 Jan 2007
  20. **Cancer Research UK Biomarkers and Imaging Discovery and Development committee (BIDD) Award. C12540/A13230.** Lead Application **JS de Bono**, G Attard, Mr. Roger A'hern, Prof A Ashworth, Prof D Dearnaley, Prof Rosalind Eeles, Dr Emma Hall, Dr. S Harland, Dr C Jameson, Dr R Jones, Dr C Lord, Prof M Mason, Dr Shahneen Sandhu. "Identification And Molecular Characterisation of Metastatic Sporadic Castration Resistant Prostate Cancers (mCRPC) With Homologous Recombination DNA Repair Defects That Can Be Targeted by a Synthetic Lethal Strategy. 1 August 2011 – 31 July 2014 total £282970.00 (Year 1 £91,329.38.)
  21. **Cancer Research UK. C12540/A12829** Prof **JS de Bono**, Mr R A'Hern, Prof A Ashworth, Prof D Dearnaley, Prof R Eeles, Dr E Hall, Dr S Harland, Dr C Jameson, Dr R Jones, Dr C Lord, Prof M Mason, Dr S Sandhu. TO-PARP: Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer. Activation from 1 Aug
  22. **Prostate Cancer Foundation Challenge Award. Prof JS de Bono**, Dr G Attard, J Luo, M Carducci, M Eisenberger (Johns Hopkins University), P Campbell (The Sanger Centre). "Reversing Drug Resistance in Castration Resistant Prostate Cancer" June 2011 August 2013 \$1,000,000;
  23. **Biomedical Research Centre Grant.** Prof S B Kaye, Prof P Workman, Prof M Leach, Prof N De Souza, Prof A Pearson, Prof Gareth Morgan, Dr F Davies, Dr U Banerji, Dr R Molife, Dr F Raynaud and Dr M Garrett. 2011-2016
  24. **CTAAC Cancer Research UK. TO-PARP: Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer. Prof JS de Bono**, Mr. Roger A'hern, Prof A Ashworth, Prof D Dearnaley, Prof Rosalind Eeles, Dr Emma Hall, Dr. S Harland, Dr C Jameson, Dr R Jones, Dr C Lord, Prof M Mason, Dr Shahneen Sandhu. 1 March 2011 to 28 February 2014. Total £231,601.00.
  25. **C309/A11566 Cancer Research UK** Quinquennial Review Award 2010 10/1/2011 –09/30/2016. Workman P, **JS de Bono co-investigator** £6,741,796. Project goal: Funding of salaries (79.71 full-time equivalent), capital equipment and equipment maintenance, laboratory and office expenses, travel
  26. **AstraZeneca No 41806** Dr G Attard, **JS de Bono co-investigator**. January 2012-January 2014. £250,000 Preclinical and biomarker strategies to maximize the AZ SARD anticancer drug development program for the treatment of patients with advanced castration-resistant prostate cancer.
  27. **Cancer Research UK C35118/A13239** 08/01/2012 –08/01/2016 **Dr G Attard JS de Bono**. Identifying novel biomarkers-driven therapeutic strategies for castration-resistant prostate cancer. £718,000.
  28. **Cancer Research UK Centre at the Institute of Cancer Research and Royal Marsden Ref: C347/A15403.** 36 Months from 1 January 2012 3 elements, core, clinical and training.
  29. **Academy of Medical Sciences & Wellcome Trust Starter Grant for Clinical Lecturer: AMS/ICR/00.** 09/01/2010 – 09/01/2012. Dr G Attard and **JS de Bono**. Why do prostate cancer patients become resistant to endocrine therapy. £30,000
  29. **Stand up to Cancer (SU2C) A1100157 JS de Bono with The Prostate Cancer Foundation.** Precision therapy of advanced prostate cancer. A collaboration with University of Michigan, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute Harvard, Fred Hutchinson Cancer Research Center, University of Washington and the Institute of Cancer Research/Royal Marsden NHS Foundation Trust. 1 September 2012 – 31 August 2013
  30. **EuroCan FP7 305341** Circulating Tumor Cell Therapeutic Apheresis (CTCTRAP): a novel biotechnology enabling personalized therapy for all cancer patients. Collaborative project between University of Twente (UT), The Netherlands Terstappen –coordinator), Institut Gustave Roussy, France. ICR, Institute of Cancer Research – Royal Cancer Hospital, Johann de Bono) UFT, Eberhard Karls Universität Tübingen, Germany, LMU, Ludwig-Maximilians University, Germany, BRC, Biological Research Centre of the Hungarian Academy of Science, Hungary, IOV, Oncology Institute of Veneto IRCCS, Italy, LKC, Leukocare, Germany. ASB, Asper Biotech, Estonia, ACZ, Aczon, Italy, AQ, Aquamarijn, The Netherlands. JS de Bono Co investigator and PI for the ICR and RMH. €800,000 awarded to JS de Bono team from a total of €6.8 million. July 2012
  31. **DOD PC121152** "Targeting the Aberrant Androgen Receptor in Advanced Treatment-Resistant Prostate Cancer" 1/10/2013 – 1/10/2016 \$356,910pa.
-

32. **Prostate Cancer Foundation PCF-Movember Challenge Award.** G Attard and **JS de Bono** Interrogating DNA Repair Defects to Improve Management of Advanced PCa. 15/10/2012-15/10/2014. \$500,000.
33. **Prostate Cancer Foundation Challenge Award. JS de Bono & Dr G Attard.** Defining the clinical relevance of intratumor heterogeneity and subclonal evolution in prostate cancer. 15/10/2012-15/10/2014 . \$500,000.
34. **Prostate Cancer UK. Grant Ref PG12-49.** G Attard, **de Bono JS (co-investigator)**. Using circulating plasma DNA as a multi-purpose biomarkers to identify aggressive prostate cancer and mechanisms of drug resistance. 2 years 01/04/2013-01/0-4/2015 £245,867.
35. **C12540/A15573 Cancer Research UK Scientific Executive Board Experimental Cancer Medicine Centre Network award.****Title: ICR ECMC.** The specific aim of the Experimental Cancer Medicine Centre at the Royal Marsden Hospital/ICR is to consolidate its international leadership position in the conduct of early phase clinical trials by treating the maximum number of patients, while developing and validating response measures and collaborating with other ECMC sites. It will continue to run 25 – 30 Phase I trials at any one time and conduct hypothesis-testing biomarker-driven trials focusing on the evaluation of drug tolerability and the establishment of the maximum tolerated dose. 4/1/2012 – 31/3/2017 £250,000 (Year 1)
36. **Prostate Cancer UK, Grant Ref. PG13-036, de Bono JS Lead Applicant.** CHD1 Deletion: Implications to Outcome and Treatment in Prostate Cancer. 3 years 01/04/2014 – 1/04/2017, £393,414
37. **London Movember Prostate Cancer Centre, Ref. CEO13-2-002, de Bono J Director of Centre.** Harnessing germline and tumour (tissue and plasma) genomic changes for targeted screening and more precise prostate cancer care. 5 years 2014/2019, £5,204,881

**GMC Number: 3352786**

Signed:

A handwritten signature in black ink, appearing to read 'Juan de Bono', written in a cursive style.

Date: 19 September 2014

---